GLYLO Supplement Pilot Trial on Glycation and Aging in Post-menopausal Women

NCT06813261

Status	RECRUITING
Phase	Not Applicable
Sponsor	Buck Institute for Research on Aging
Enrollment	30 participants

Key Eligibility Criteria

Inclusion (9)

- Adults identified as female at birth with ovaries present (self-report)
- Post menopause \>1y since last menses (self-report)
- Aged 45 - 65 y
- Anthropometric criteria (either of the following must be met):
- BMI e 25 kg/m², based on self-reported weight and height

... and 4 more (see full listing online)

Exclusion (23)

- Surgical menopause (self-report)
- Hysterectomy and/or ovariectomy (self-report)
- Receiving systematic hormone replacement therapy (HRT) (self-report). Use of local vaginal estrogen therapy (e.g., estrogen creams, vaginal tablets, or estrogen rings such as Estring) is permitted.
- Currently prescribed or received weight loss medications within the past 6 months or currently enrolled in a defined weight loss program. Weight must be stable (\> 4%) within the last 3 months.
- Regular use of GLYLO, or regular use of a supplement containing any of the ingredients in GLYLO, within the last 3 months.

... and 18 more (see full listing online)

Locations (1 total)

The Buck Institute for Research on Aging, Novato, California, United States